Table 4:
Development of MODS based on PERSEVERE biomarkers
| Biomarkers at 4 hours | ||
|---|---|---|
| OR (95% CI) | p-value | |
| GZMB | 0.79 (0.20; 1.18) | 0.524 |
| HSP70 | 0.94 (0.35; 1.35) | 0.852 |
| IL-1a | 1.08 (0.50; 1.45) | 0.684 |
| IL-8 | 1.94 (1.41; 2.77) | <0.001 |
| CCL3 | 1.07 (0.74; 1.49) | 0.700 |
| CCL4 | 1.21 (0.88; 1.64) | 0.210 |
| MMP-8 | 1.15 (0.69; 1.60) | 0.473 |
| Biomarkers at 12 hours | ||
| OR (95% CI) | p-value | |
| GZMB | 1.42 (1.04; 1.88) | 0.012 |
| HSP70 | 1.27 (0.89; 1.65) | 0.081 |
| IL-1a | 0.69 (0.18; 1.23) | 0.394 |
| IL-8 | 11.42 (2.91; 57.11) | 0.001 |
| CCL3 | 1.36 (1.02; 1.84) | 0.038 |
| CCL4 | 1.27 (0.92; 1.71) | 0.125 |
| MMP-8 | 0.99 (0.46; 1.44) | 0.963 |
Odds ratios (OR) obtained via logistic regression. Each biomarker was modeled separately. All models adjusted for age less than 12 months (infant), STAT mortality category, single ventricle status, and time (in minutes) on cardiopulmonary bypass. CI: confidence interval; ; GZMB, granzyme B; HSPA1B, heat shock protein 70 kDa 1B; IL-1a interleukin 1a; IL-8, interleukin 8; CCL3, C-C chemokine ligand 3; CCL4, C-C chemokine ligand 4; MMP-8, matrix metalloproteinase 8